Study | Sample size | Age, (year)a | Malesb | Duration of symptomsa | Dominant hand, Rt-Ltb | Involved had, Rt-Ltb | Follow up, months | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | ||
Eftekharsadat et al. [9] (100 mg) | 30 | 15 | 42.46 (8.16) | 46.34 (8.08) | 6 (20) | 2 (6.67) | 21.56 (7.34) | 21.33 (7.45) | 28–2 (93.3–6.7) | 27–3 (90–10) | 18–12 (60–40) | 19–11 (63.3–36.7) | 2 |
Eftekharsadat et al. [9] (300 mg) | 30 | 15 | 44.56 (8.58) | 46.34 (8.08) | 9 (30) | 3 (10) | 20.32 (7.93) | 21.33 (7.45) | 23–7 (76.7–23.3) | 27–3 (90–10) | 18–12 (60–40) | 19–11 (63.3–36.7) | 2 |
Hesami et al. [10] (300 mg) | 23 | 20 | 41.04 (8.46) | 48.30 (9.96) | 0 (0) | 4 (20) | ND | ND | ND | ND | ND | ND | 1 |
Mehmetoglu et al. [11] (1800 mg) | 28 | 30 | 47.125 (3.107) | 47.8 (4.66) | 2 (7.14) | 6 (20) | 18.75 (5.22) | 24 (4.5) | 28–0 (100–0) | 24–6 (80–20) | 15–13 (53.6–46.4) | 15–15 (50–50) | 6 |